Opinion|Videos|April 7, 2025
BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status
Author(s)John L. Marshall, MD, Mark Lewis, MD
Panelists discuss how BESPOKE trial results demonstrate significantly improved disease-free survival rates in patients with negative circulating tumor DNA (ctDNA) status compared with those with detectable ctDNA, underscoring its potential as a powerful prognostic biomarker.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ryosuke Tateishi, MD, PhD, discussed lifestyle interventions, surveillance, and what the US and Japan can share to prevent MASLD-related liver cancer.
Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.
Psychiatrists explain where ketamine and esketamine show real promise for depression in patients with cancer and where caution is still needed.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
4
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
5